Osteogenesis imperfecta or 'brittle bone disease' has mainly been considered a bone disorder caused by collagen mutations. Within the last decade, however, a surge of genetic discoveries has created a new paradigm for osteogenesis imperfecta as a collagen-related disorder, where most cases are due to autosomal dominant type I collagen defects, while rare, mostly recessive, forms are due to defects in genes whose protein products interact with collagen protein. This review is both timely and relevant in outlining the genesis, development, and future of this paradigm shift in the understanding of osteogenesis imperfecta.
INTRODUCTION
Osteogenesis imperfecta or 'brittle bone disease' is a heritable bone dysplasia resulting in fragile, deformed bones, short stature, and, usually, low bone mass. The current osteogenesis imperfecta paradigm is that of a collagen-related bone dysplasia, with most dominant cases caused by defects in type I collagen itself, while rare recessive forms are caused by defects in genes whose products interact with collagen [1, 2] . The classical osteogenesis imperfecta types I-IV contain the majority of cases (Table 1) ; they are dominantly inherited and caused by mutations in COL1A1 or COL1A2, producing defects in type I collagen quantity or structure [3] . Osteogenesis imperfecta types V and peptidase inhibitor, clade F, member 1 (SERPINF1), were identified [4] . Types VII-XII, with autosomal recessive inheritance, were delineated as their causative genes were identified. Osteogenesis imperfecta types VII-IX have defects in the collagen prolyl 3-hydroxylation complex (Table 1 ; Fig. 1b) , which alter the post-translational modification of collagen [5, 6] . Osteogenesis imperfecta types X and XI affect collagen folding and chaperone functions and are caused by mutations in SERPINH1 and FKBP10 [2] . Finally, absence of the type I collagen C-propeptide-processing enzyme, BMP1, results in osteogenesis imperfecta type XII [7] . A functional grouping of types of osteogenesis imperfecta by shared collagen-related mechanism was recently proposed [Marini, personal communication] .
DEFECTS IN COLLAGEN SYNTHESIS, STRUCTURE OR PROCESSING: MUTATIONS IN COL1 AND BMP1
Type I collagen is a heterotrimer synthesized as a procollagen precursor containing two proα1(I) and one proα2(I) polypeptide chains, encoded by the COL1A1 and COL1A2 genes, respectively. Procollagen undergoes post-translational modifications in the endoplasmic reticulum during chain synthesis and helix formation. Short N-propeptide Table 1 . Osteogenesis imperfecta types caused by defects in genes and the collagen-related proteins that they encode
OI type
Defective gene Defective protein Defective mechanism
Autosomal dominant
The mode of inheritance for the osteogenesis imperfecta types is shown on the left, with the proportion of known osteogenesis imperfecta cases on the right. The current nosology is shown only up to type XII, after which the osteogenesis imperfecta types remain largely unclassified. The majority (85-90%) of osteogenesis imperfecta cases, resulting from defects in collagen genes and subsequent defective quantitative and qualitative (structural) mechanisms, are listed as types I-IV. Defects in IFITM5 and SERPINH1 result in the mineralization defects seen in most osteogenesis imperfecta types V and VI, respectively. Defects in CRTAP, LEPRE1, and PPIB result in the collagen 3-hydroxylation defects of most cases of osteogenesis imperfecta types VII, VIII, and IX, respectively. Defects in SERPINH1 and FKBP10 result in the collagen chaperoning and hydroxylation defects of osteogenesis imperfecta types X and XI, respectively. Defects in BMP1 result in the collagen-processing defects of osteogenesis imperfecta type XII. Defects in the relatively novel osteogenesis imperfecta genes SP7/OSX, WNT1, TMEM38B, and CREB3L1 result in osteoblast differentiation defects of separate, currently unclassified osteogenesis imperfecta cases/types. CRTAP, cartilage-associated protein; LEPRE1, leucine and proline-enriched proteoglycan 1; mTLD, mammalian tolloid protein; OI, osteogenesis imperfecta; PPIB, peptidyl-prolyl cis-trans isomerase B.
KEY POINTS
• The current osteogenesis imperfecta paradigm is that of a collagen-related bone dysplasia, with most dominant cases caused by defects in type I collagen itself and producing defects in type I collagen quantity or structure.
• Within the last decade, a flood of genetic discoveries has generated a new paradigm for osteogenesis imperfecta as a collagen-related disorder, in which autosomal dominant defects in the structure or synthesis of type I collagen are responsible for the great majority of cases, while rare, mostly recessive, forms of osteogenesis imperfecta are caused by defects in genes whose protein products interact with collagen post-translationally and whose critical role in normal bone development had not been previously appreciated.
• The collagen-related proteins are involved in collagen modification (members of the collagen prolyl 3-hydroxylation complex: CRTAP, P3H1, and CyPB), collagen mineralization (BRIL and PEDF), collagen folding, crosslinking, and chaperoning (HSP47 and FKBP65), and osteoblast development [osterix (OSX), WNT1, TRIC-B, and OASIS].
• Investigations of common pathways in dominant and recessive osteogenesis imperfecta can be expected to yield critical insights into mechanism at cellular and bone tissue levels.
and C-propeptide domains flank the central helical domain, which contains uninterrupted Gly-Xaa-Yaa tripeptides, where X is often proline and Y is hydroxyproline. Procollagen maturation entails cleavage of the propeptides by specific N-terminal and C-terminal propeptidases [8] . Defects in either structure or synthesis of type I collagen can cause osteogenesis imperfecta. The novel osteogenesis imperfecta proteins all affect osteoblast development: specifically, nuclear OSTERIX affects osteoblast differentiation genes, the trimeric TRIC-B channel affects intracellular Ca 2+ signaling, the endoplasmic reticulum-stress transducer OASIS modulates Col1 transcription when nuclear, and WNT1 binds LRP5 to affect bone formation. (b) Green arrows show the normal effect of the proteins on collagen. The endoplasmic reticulum-resident complex of CRTAP/P3H1/CyPB 3-hydroxylates specific prolines on the α1(I) and α2(I) chains, while chaperones contribute to normal folding of the collagen trimer. BRIL, bone-restricted IFITM-like protein; CRTAP, cartilage-associated protein; CyPB, cyclophilin B; OASIS, old astrocyte specifically induced substance; PEDF, pigment epithelium-derived factor; P3H1, prolyl 3-hydroxylase 1.
Dominantly inherited types of osteogenesis imperfecta include mild, non-deforming type I, perinatal lethal type II, progressively deforming type III, and moderately deforming type IV. Mutations in either the COL1A1 or the COL1A2 gene can cause the structural defects in collagen that underlie osteogenesis imperfecta types II-IV. In contrast, a null COL1A1 allele causes osteogenesis imperfecta type I, in which structurally normal type I collagen is synthesized at about half the normal amount. The collagen insufficiency of osteogenesis imperfecta type I generally results from mutations causing premature termination, with nonsense-mediated mRNA decay of defective transcripts from the mutant allele, leaving only the structurally normal collagen from the normal allele [2, 3] . Over 80% of the mutations altering type I collagen structure are single base-pair changes resulting in substitutions of glycine residues in either the α1(I) or α2(I) chain. The larger side chain of the substituting residue causes a delay in helix folding and subsequent post-translational overmodification of lysine and proline residues along the length of the helical region. Phenotypic severity varies with amino acid substitution, chain, and position [1, 3] . A set of fascinating mutations, causing an autosomal dominant high bone mass phenotype, alters the C-propeptide cleavage site [9] . Interestingly, mutations in BMP1, encoding the C-propeptidase of type I procollagen, cause a recessive counterpart to high bone mass osteogenesis imperfecta (osteogenesis imperfecta type XII; Fig. 1a ) [7] . Conversely, mutations in the N-propeptide cleavage site, the N-anchor domain of the helical region, or the N-propeptidase ADAMTS-2 cause Ehlers-Danlos syndrome (EDS) or osteogenesis imperfecta/EDS phenotypes [10] .
DEFECTS IN COLLAGEN MODIFICATION: MUTATIONS IN 3-HYDROXYLATION COMPLEX COMPONENTS (CRTAP, LEPRE1, PPIB)
Cartilage-associated protein (CRTAP), prolyl 3-hydroxylase 1 (P3H1), and cyclophilin B (CyPB) were the first proteins linked to recessive osteogenesis imperfecta, specifically causing types VII, VIII, and IX, respectively [11] [12] [13] [14] [15] . These three proteins associate in 1:1:1 proportion to form the endoplasmic reticulum-localized collagen prolyl 3-hydroxylation complex (Fig. 1b) . This complex modifies discrete collagen proline residues, specifically, α1 (I)/α1(II) Proline-986 and α2(I) Proline-707, while the collagen chains are unfolded [1] . It also has peptidyl prolyl cis-trans isomerase (PPIase) activity and is a collagen chaperone [16] . It is not yet clear whether it is the absence of the complex or the collagen 3-hydroxylation modification that causes the bone dysplasia.
CRTAP, the 'helper' in the complex, is mutually protective with P3H1 in the endoplasmic reticulum, so that absence of either protein results in absence of both proteins [17] . CRTAP was first identified in cartilage and is expressed in multiple tissues [15] . Normally, up to 12% of the CRTAP produced by dermal fibroblasts is secreted; therefore, it may have an additional role in extracellular matrix [17] . Loss of the matrix function of CRTAP, speculated to affect supramolecular assembly, may exacerbate the bone dysplasia in osteogenesis imperfecta type VII and cause renal and lung defects. Patients with CRTAP deficiency have no prolyl 3-hydroxylation complex and, consequently, absent α1(I) Proline-986 hydroxylation [13] . Conversely, overmodification of the collagen helix in type VII proband cells by lysyl hydroxylase and prolyl 4-hydroxylase suggests delayed helix folding. Clinical presentations include severe-to-lethal osteochondrodysplasia with rhizomelia, neonatal fractures, broad undertubulated long bones, fragile ribs, severe growth defects, and 'popcorn' epiphyseal calcifications in the occasional survivors [5, 18] .
P3H1 (the enzyme in the complex) was first described as the matrix proteoglycan leprecan and is encoded by the leucine and proline-enriched proteoglycan 1 (LEPRE1) gene. P3H1 may function in both the extracellular matrix and the endoplasmic reticulum/Golgi compartments via its RGD (Arg-GlyAsp) cell adhesion domain and a KDEL (Lys-Asp-GluLeu) endoplasmic reticulum-retention sequence, respectively, but the relative contribution of these roles to bone development is unknown [5] . Osteogenesis imperfecta type VIII, caused primarily by null LEPRE1 alleles, is clinically similar to osteogenesis imperfecta type VII. The most common LEPRE1 allele is a founder mutation originating in West Africa that has also been reported in patients of African-American ancestry [19] . Type I collagen from LEPRE1-null cells is overmodified, as in osteogenesis imperfecta types II-IV and VII, with an unanticipated 50% increase in collagen production versus controls [14] .
CyPB, encoded by the peptidyl-prolyl cis-trans isomerase B (PPIB) gene, is the third protein in the 3-hydroxylation complex. Peptidyl-prolyl cis-trans isomerization is the rate-limiting step in folding of the collagen helix, and CyPB was long considered the unique PPIase for this function. CyPB is ubiquitously expressed and its stability is independent of CRTAP/P3H1. PPIB-null cells, however, have moderately reduced CRTAP and P3H1 protein levels, suggesting CyPB provides some support to the complex [12, 17] . Only eight cases with PPIB defects have been reported, of which four have biochemical studies. Two lethal cases have 30% α1(I) Pro986 3-hydroxylation and overmodification of the collagen helix [1] . Collagen overmodification in these cases may result from absence of the PPIase role of CyPB. Two moderately severe cases have normal α1(I) Pro986 3-hydroxylation, suggesting that the CRTAP/P3H1 complex can function in the total absence of CyPB. In addition, the case with a PPIB start codon mutation has normal levels of collagen helical modification, suggesting that another PPIase can contribute to collagen folding [12] . Collectively, the features of osteogenesis imperfecta types VII-IX can be considered manifestations of defects in collagen modification.
DEFECTS IN MINERALIZATION: MUTATIONS IN SERPINF1 AND IFITM5
Osteogenesis imperfecta types V and VI (Fig. 1a) have unique clinical phenotypes, characterized by distinct defects in bone mineralization [20, 21] . Patients with osteogenesis imperfecta type V have dominant inheritance of moderately severe bone dysplasia and fracture incidence, including vertebral compressions and, often, scoliosis. Features of osteogenesis imperfecta type V include radial head dislocation, ossification of the forearm interosseous membrane, and hyperplastic callus. There is also a radiographically dense band prominent in the forearm metaphyses. The combination of features present in any given patient is variable, as is the timing of appearance. All patients with osteogenesis imperfecta type V have a distinctive mesh-like lamellation pattern on bone histology [20, 22] .
Patients with osteogenesis imperfecta type VI have recessive inheritance of bone dysplasia, with clinical characteristics and bone histology distinct from osteogenesis imperfecta type V. They do not have fractures at birth, but later have frequent fractures, progressive bone deformity, vertebral compressions, and scoliosis. Growth deficiency in osteogenesis imperfecta type VI is moderately severe, sclerae are white, and teeth are normal. Children with osteogenesis imperfecta type VI have elevated serum alkaline phosphatase levels, with a mean of 409 U/l (range 200-650 U/l). Bone histology is remarkable for broad bands of unmineralized osteoid and a fish-scale pattern under polarized light [21, 23] .
Recently, the genes responsible for osteogenesis imperfecta types V and VI have been delineated. All cases of osteogenesis imperfecta type V are caused by a recurrent heterozygous mutation (c.-14C>T) in the 5'-untranslated region (UTR) of IFITM5, which encodes bone-restricted IFITM-like protein (BRIL), previously known as 'IFITM5' , a transmembrane protein enriched in osteoblasts during mineralization [24] . The osteogenesis imperfecta type V mutation putatively adds five amino acids to the N-terminus of BRIL and may have a gain-of-function mechanism [25, 26] . The causative gene for osteogenesis imperfecta type VI is SERPINF1, which encodes pigment epitheliumderived factor (PEDF) [27, 28] . PEDF is a ubiquitously expressed secreted protein best known as a potent anti-angiogenic factor that inhibits tumor growth and metastasis [29] . PEDF binds to two distinct sites on type I collagen, and this binding is critical to its anti-angiogenic function [30] . A variety of recessive null mutations in SERPINF1 have been reported [27, 28, 31, 32] . Serum PEDF is virtually absent in patients with osteogenesis imperfecta type VI, while normal PEDF values are reported in patients with osteogenesis imperfecta type V, as well as in osteogenesis imperfecta caused by collagen defects (types I, III, and IV) [31] .
The connection between BRIL and PEDF, and, hence, osteogenesis imperfecta types V and VI, was revealed by a novel heterozygous IFITM5 mutation (p.S40L) in the intracellular domain of BRIL [33 && ,34,35] . Interestingly, the patient with the BRIL S40L substitution had no features of osteogenesis imperfecta type V, but instead had severe osteogenesis imperfecta with bone histology typical of osteogenesis imperfecta type VI. The dermal fibroblasts and cultured osteoblasts of the patient displayed minimal secretion of PEDF, implying a connection between BRIL and PEDF functions in bone mineralization. Osteoblasts from a typical case of osteogenesis imperfecta type V, with extended BRIL N-terminus, have increased SERPINF1 expression and PEDF secretion during osteoblast differentiation. Together, these data suggest that the osteogenesis imperfecta type V mutation causes gain of function while p.S40L causes loss of BRIL function in bone development [33 && ].
DEFECTS IN COLLAGEN CHAPERONES AND FOLDASES: MUTATIONS IN SERPINH1 AND FKBP10
Osteogenesis imperfecta types X and XI (Fig. 1b) are caused by mutations in the SERPINH1 and FKBP10 genes, respectively. The protein products of these genes, HSP47 and FKBP65, respectively, play crucial roles in the proper folding of triple helical procollagen molecules. FKBP65 is also a PPIase [36] .
HSP47 (encoded by SERPINH1 gene) preferentially binds toward the N-terminus of triple helical procollagen, stabilizes the folded collagen in the endoplasmic reticulum, and assists shuttling of correctly folded collagen into the cis-Golgi. Only two SERPINH1 mutations causing bone dysplasia have been reported: one is a recessive SERPINH1 missense mutation (c.977T_C) in Dachshunds [37] and the other is a homozygous missense mutation (c.233T_C, p.Leu78Pro) in the only case of osteogenesis imperfecta type X, whose clinical course was progressive and severe, with features both typical and atypical of osteogenesis imperfecta [38] . Mutant transcripts were stable, but HSP47 protein was substantially degraded. Residual HSP47 function likely enabled the survival of the child for 3 years, since Serpinh1-null mice are embryonic lethal [39] . Knockout mice have aggregation of collagen in the cell, delayed secretion, and abnormal fibrillogenesis [40] , while the collagen of the patient had near-normal collagen modification and secretion, despite increased site-specific susceptibility to proteolysis, again supporting residual function of the missense-containing HSP47.
Defects in FKBP10 (encoding FKBP65) have been particularly interesting, in that they encompass a spectrum of disorders formerly thought to be unrelated, that is, osteogenesis imperfecta and Bruck and Kuskokwim syndromes. FKBP10 mutations were first delineated in moderately severe osteogenesis imperfecta [41] . Shortly thereafter, Bruck syndrome I, a recessive disorder of severe osteogenesis imperfecta with congenital contractures, was also shown to result from FKBP10 mutations [42] . Since contractures are not always present in patients with the same FKBP10 mutation, even in siblings, it became clear that osteogenesis imperfecta and Bruck syndrome I were allelic conditions with variable contracture manifestation. Bruck syndrome can also be caused by mutations in procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2) [43 && ], which encodes lysyl hydroxylase 2 (LH2), the enzyme responsible for hydroxylation of collagen telopeptide lysine. Finally, Kuskokwim syndrome, a congenital contracture syndrome with minimal skeletal manifestations that occurs among the Yup'ik Eskimos of Alaska, was traced to an in-frame deletion of a conserved tyrosine in the third PPIase domain of FKBP65 [44 && ]. Collagen secreted from FKBP10-defective cells exhibited normal helical modification and α1(I) Pro986 3-hydroxylation. However, collagen Ctelopeptide lysines from fibroblasts with null FKBP10 mutations showed less than 1% hydroxylation versus 60% in normal cells [44 && ], a finding corroborated by data from bone tissue [45] 
UNCLASSIFIED/NEW GENES
In the past few years, several genes found to cause osteogenesis imperfecta appear to primarily affect osteoblast differentiation (Fig. 1a) . First, a homozygous deletion (c.1052delA) was identified in SP7/ OSTERIX (OSX) in an Egyptian child with recessive osteogenesis imperfecta [46] . In mice, Osx is essential for bone formation. Osx-null mice show deficient osteoblast differentiation, reduced expression of osteoblast markers, including Col1a1, and bone bending deformities similar to those of patients with osteogenesis imperfecta [47] .
Next, mutations in WNT1 were identified in multiple cases of osteogenesis imperfecta [48,49 & ,50,51] . Heterozygous mutations lead to osteoporosis while several homozygous mutations cause severe osteogenesis imperfecta [50] . A number of WNT family members are key regulators of bone mass through β-catenin. WNT interacts with the cell surface low-density lipoprotein receptor-related protein 5 (LRP5) to activate bone formation. Homozygous defects in lipoprotein receptor-related protein 5 cause juvenile osteoporosis, resembling osteogenesis imperfecta type IV in its skeletal features [52] . The Wnt1 knockout mouse has severe abnormalities in brain development, but no reported skeletal phenotype. Conversely, only one of the patients with osteogenesis imperfecta reported with WNT1 mutations had a neurodevelopmental defect [53] .
Third, a founder mutation (p.Gly152Alafs*5) in TMEM38B that deleted exon 4, causing premature termination, was identified in autosomal recessive osteogenesis imperfecta among Bedouins from Saudi Arabia and Israel [54, 55] . TMEM38B encodes TRIC-B, a monovalent cation-specific channel involved in intracellular Ca 2+ release and active in cell differentiation. Tmem38b-knockout mice show neonatal lethality; thus, the skeletal phenotype was not determined [56] . Alteration in TRIC-B might lead to autosomal recessive osteogenesis imperfecta through defective intracellular Ca 2+ signaling in bone cells. Most recently, a homozygous genomic deletion of CREB3L1 gene, encoding old astrocyte specifically induced substance (OASIS), was reported in a family with severe osteogenesis imperfecta [57 & ]. OASIS is an endoplasmic reticulum-stress transducer that regulates genes involved in developmental processes, differentiation, and maturation. Creb3l1-knockout mice have severe osteopenia and spontaneous fractures, and OASIS was shown to activate the transcription of Col1a1 [58] .
CONCLUSION
Within the last decade, a virtual flood of genetic discoveries has generated a new paradigm for osteogenesis imperfecta as a collagen-related disorder, in which autosomal dominant defects in the structure or synthesis of type I collagen are responsible for the great majority of cases, while rare, mostly recessive, forms of osteogenesis imperfecta are caused by defects in genes whose protein products interact with collagen post-translationally. In addition to the identification of causative defects providing the information essential for accurate genetic counseling, each of these discoveries has revealed proteins whose critical role in normal bone development had not been previously appreciated. The collagen-associated proteins are involved in collagen modification (members of the collagen prolyl 3-hydroxylation complex: CRTAP, P3H1, and CyPB), collagen mineralization (BRIL and PEDF), collagen folding, crosslinking, and chaperoning (HSP47 and FKBP65), and osteoblast development (SP7, WNT1, TRIC-B, and OA-SIS). Investigations of common pathways in dominant and recessive osteogenesis imperfecta can be expected to yield critical insights into mechanism at cellular and bone tissue levels. The dynamism of osteogenesis imperfecta research continues, with additional novel genes on the horizon and the potential to translate new understanding of mechanism into clinical therapies for affected individuals. Additionally, a novel approach to categorizing existing types of osteogenesis imperfecta based on connected metabolic mechanisms should prove effective in simplifying current nosology.
